Bob leads Applied Molecular Transport’s product development activities focused on advancing the company’s products through development and positioning a deep pipeline development capability for novel biopharmaceutical candidates generated by the company’s platform technologies. With an industry career that has spanned more than 30 years in pre-clinical and clinical research positions at organizations that include Lederle Laboratories, Genentech, Emisphere and MannKind, he has advanced many programs to the clinic and launched highly complex biological therapeutic products. Bob is an active member of the American Diabetes Association and the American Association of Pharmaceutical Scientists (AAPS), where he served as Treasurer and member of the AAPS Executive Council, and Chairman of the AAPS Biotechnology Section.  He served on the Advisory Board of the American College of Clinical Pharmacology, the Editorial Board of the International Journal of Clinical Pharmacology and Therapeutics, and the Board of Advisors of BioEthics International.  He holds adjunct faculty appointments in the College of Pharmacy and the Graduate School at the University of Florida. Bob received his undergraduate degree in Biology from Loyola University, Los Angeles and earned his doctorates in Clinical Pharmacy (PharmD) and Pharmaceutical Chemistry (PhD) from the University of California, San Francisco.

Robert A. Baughman, PharmD, PhD

Chief Development Officer

Helen S. Kim

Strategic Advisor

Randall Mrsny, PhD

Chief Science Officer & Co-founder

LEADERSHIP

Tahir Mahmood, PhD

CEO & Co-founder

Copyright © APPLIED MOLECULAR TRANSPORT INC. 2016. All rights reserved.

​​​​​​​​Tahir co-founded Applied Molecular Transport, where he also leads the company’s partnering and corporate development activities. With a career that has straddled science and business, Tahir previously led the US West Coast Life Sciences consulting practice at Booz Allen Hamilton and was Managing Director at Lake Sherwood Partners. As a consultant, he advised executives across the spectrum of life sciences, healthcare provider, private and public equity investment, and global health organizations. Tahir is also co-founder and Board Director of MiNDERA, a molecular diagnostics company with a technology platform he co-invented and developed as an investigator at The Scripps Research Institute. He served as Principal Business Analyst at Amgen, supporting BD, M&A and strategic venture fund transactions related to pharmaceutical technology and drug delivery. Earlier, he was at Chienna (acquired by OctoPlus) and IsoTis S.A. (acquired by Integra Life Sciences). Tahir has authored numerous peer-reviewed publications and is inventor on issued and pending patents. He received BASc and MSc degrees from the University of Toronto. He holds a PhD in Chemical & Biomedical Engineering from a collaborative program between the University of Twente (The Netherlands) and Massachusetts Institute of Technology at the Harvard-MIT Division of Health Sciences and Technology and Boston Children’s Hospital.

Weijun leads Applied Molecular Transport's Protein Science function, with responsibility for new molecular construct design, protein engineering and manufacturing scale-up. He overseas candidate optimization for all Program Teams as well as upstream and downstream Process Development. Previously, Weijun was Associate Director at Five Prime Therapeutics in its Antibody/Protein Engineering and Process Development group where he designed and executed biologicals GMP downstream process development and developed an antibody-targeted novel therapeutic protein platform.  He was also at Neugenesis Corp (Antibody Process Development Science) and Signature BioScience. Before joining the biotechnology industry, Weijun practiced clinical medicine in Endocrinology and Oncology as Resident and Research Fellow at the Shanghai Institute of Pediatric Research. He graduated as Medical Doctor (MD) from Shanghai Second Medical University, received a PhD in Pharmacology at the University of Nebraska Medical Center, and was Postdoctoral Fellow at the Center for Diabetes, Endocrine and Metabolic Disorders at UCSF.

An epithelial biologist, Randy has more than three decades of industry and academic experience in pharmaceutical sciences, drug development, and research into the mucosal trafficking of peptide and protein therapeutics. He leads Applied Molecular Transport’s R&D activities focused toward the generation and development of therapeutic candidate molecules. Previously, he led research groups at Genentech (Drug Delivery/Biology) and ALZA (Peptide Biology), and has held academic positions at Cardiff University (Wales) and most recently at the University of Bath (England), where he took the Professor’s Chair of Epithelial Cell Biology. His university research has focused on finding novel methods to treat inflammatory conditions and epithelial-derived cancers. Randy has served as an advisor to governments and multinational agencies and is the recipient of many awards and commendations, including being elected as President and to the College of Fellows of the Controlled Release Society. He obtained a BS in Biochemistry and Biophysics at the University of California at Davis, a PhD in Anatomy and Cell Biology at the U.C. Davis School of Medicine, and was a NIH Postdoctoral Fellow in Membrane Biophysics in the Institute of Molecular Biology at the University of Oregon. 

Weijun Feng, MD, PhD

Head of Protein Science

Helen is Strategic Advisor at Applied Molecular Transport, where she is involved with a wide range of business development, financing, corporate strategy and operational matters. She also serves as a Director of Sunesis Pharmaceuticals, Forsight VISION 4, and has served as Chief Business Officer at NGM Biopharmaceuticals, Inc. Previously, she served as a Director and Chief Executive Officer of privately held TRF Pharma, Inc. She was the Chief Executive Officer and President of Kosan Biosciences Incorporated where she restructured and repositioned the company prior to successfully selling the company to Bristol-Myers Squibb in 2008. Helen's additional industry experience includes senior positions at Affymax, Onyx Pharmaceuticals, Protein Design Labs and Chiron Corporation. In addition to her industry experience, Helen also served as Chief Program Officer for the Gordon and Betty Moore Foundation. Helen received a BS in Chemical Engineering from Northwestern University and a MBA from the University of Chicago.

Maziyar Saberi, PhD

Head of Biological Sciences

​​Mazi leads Applied Molecular Transport’s Biological Sciences, providing leadership for the Company’s research and discovery efforts. He was most recently the Head of Research at Second Genome, responsible for establishing and leading discovery platforms across metabolic and inflammatory diseases. Prior to Second Genome, he was Head of Pharmacology at NGM Biopharmaceuticals, successfully establishing and leading programs related to obesity, metabolic and liver diseases. Mazi was a post-doctoral fellow at University of California, San Diego School of Medicine and has a PhD from University of Southern California.